Vaccine against streptococcus pneumoniae capsular polysaccharides

Inactive Publication Date: 2003-08-07
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF2 Cites 90 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The latter three vaccines confer protection against bacteria causing respiratory infections resulting in severe morbidity and mortality in infants, yet these vaccines have not been licensed for use in children less than two years of age because they are inadequately immunogenic in this age group [Peltola et al.
The 23-valent vaccine does not demonstrate protection against pneumococcal pneumonia (in certain high risk groups such as the elderly) and otitis media diseases.
Many are very efficient, but cause significant local and systemic adverse reactions that preclude their use in human vaccine compositions.
The practicality of using an immunization scheme that requires a delay in the administration of MPL relative to antigen, especially in infants, is questionable.
Amongst the problems associated with the polysaccharide approach to vaccination, is the fact that polysaccharides per se are poor immunogens.
Problems Associated with Commonly-Used Carriers
A number of problems are associated with each of these commonly used carriers, including i

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine against streptococcus pneumoniae capsular polysaccharides

Examples

Experimental program
Comparison scheme
Effect test

third embodiment

[0055] In a third embodiment there is provided a vaccine composition comprising a pneumococcal polysaccharide antigen and a Th1 adjuvant.

[0056] Streptococcus pneumoniae Polysaccharide Antigens of the Invention

[0057] Typically the Streptococcus pneumoniae vaccine of the present invention will comprise polysaccharide antigens (preferably conjugated), wherein the polysaccharides are derived from at least four serotypes of pneumococcus. Preferably the four serotypes include 6B, 14, 19F and 23F. More preferably, at least 7 serotypes are included in the composition, for example those derived from serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. More preferably still, at least II serotypes are included in the composition, for example the composition in one embodiment includes capsular polysaccharides derived from serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F (preferably conjugated). In a preferred embodiment of the invention at least 13 polysaccharide antigens (preferably conjugated) a...

example 1

[0149] S.pneumoniae Capsular Polysaccharide:

[0150] The 11-valent candidate vaccine includes the capsular polysaccharides serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F which were made essentially as described in EP 72513. Each polysaccharide is activated and derivatised using CDAP chemistry (WO 95 / 08348) and conjugated to the protein carrier. All the polysaccharides are conjugated in their native form, except for the serotype 3 (which was size-reduced to decrease its viscosity).

[0151] Protein Carrier:

[0152] The protein carrier selected is the recombinant protein D (PD) from Non typeable Haemophilus influenzae, expressed in E. coli.

[0153] Expression of Protein D

[0154] Haemophilus influenzae Protein D

[0155] Genetic Construction for Protein D Expression

[0156] Starting Materials

[0157] The Protein D Encoding DNA

[0158] Protein D is highly conserved among H. influenzae of all serotypes and non-typeable strains. The vector pHIC348 containing the DNA sequence encoding the entire prot...

example 2

[0204] Study of the Effect of Advanced Adjuvants on the Immunogenicity of the 11-Valent Pneumococcal PS-PD Conjugate Vaccine in Infant Rats

[0205] Infant rats were immunised with 11 valent pneumococcal PS-PD conjugate vaccine at a dosage of 0.1 .mu.g each polysaccharide (made according to the method of Example 1), and using the following adjuvant formulations: none, AlPO.sub.4, 3D-MPL, 3D-MPL on AlPO.sub.4.

[0206] The formulation with only 3D-MPL was statistically (and surprisingly) more immunogenic (greatest GMC IgG) than for the other formulations for 5 out of 11 antigens. This was true both at high and low concentrations of 3D-MPL.

[0207] Opsonophagocytosis confirmed the GMC results.

[0208] Materials and Methods

[0209] Immunisation Protocol

[0210] Infant OFA rats were randomised to different mothers and were 7 days old when they received the first immunisation. They received 2 additional immunisations 14 and 28 days later. A bleed was performed on day 56 (28 days post III). All vaccine...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Forceaaaaaaaaaa
Forceaaaaaaaaaa
Electric chargeaaaaaaaaaa
Login to view more

Abstract

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to specific advantageous pnumococcal polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid aluminium-based adjuvant.

Description

[0001] The present invention relates to bacterial polysaccharide antigen vaccines, their manufacture and the use of such polysaccharides in medicines.[0002] In particular the present invention relates to three inter-related aspects: A--vaccines comprising a pneumococcal polysaccharide antigen, typically a pneumococcal polysaccharide conjugate antigen, formulated with a protein antigen from Streptococcus pneumoniae and optionally a Th1 inducing adjuvant; B--specific, advantageous pneumococcal polysaccharide conjugates adjuvanted with a Th1 adjuvant; and C--bacterial polysaccharide conjugates in general conjugated to protein D from H. influenzae.BACKGROUND OF INVENTION[0003] Streptococcus pneumoniae is a Gram-positive bacteria responsible for considerable morbidity and mortality (particularly in the young and aged), causing invasive diseases such as pneumonia, bacteremia and meningitis, and diseases associated with colonisation, such as acute Otitis media. The rate of pneumococcal pne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61KA61K39/09A61K35/74A61K39/00A61K39/005A61K39/02A61K39/04A61K39/05A61K39/085A61K39/095A61K39/102A61K39/112A61K39/116A61K39/155A61K39/385A61K39/39A61PA61P11/00A61P27/06A61P31/04A61P37/04C07K14/285C12N15/09
CPCA61K39/092A61K39/095A61K39/102A61K39/155A61K2039/55505Y10S424/831A61K2039/6037A61K2039/6068A61K2039/6075A61K47/4833A61K2039/70A61K2039/55572A61K39/12A61K47/646A61P11/00A61P27/06A61P27/16A61P31/00A61P31/04A61P37/04Y02A50/30A61K39/385
Inventor CAPIAU, CARINEDESCHAMPS, MARGUERITEDESMONS, PIERRE MICHELLAFERRIERE, CRAIG ANTONYJOSEPHPOOLMAN, JANPRIEELS, JEAN-PAUL
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap